Biotech Values

[DewDiligence]

rph: Interesting question about the possibility of negative ramifications from non-IV administration. Would like to hear from the biology cognoscenti on this subject. In any case, I am not aware of any indication from the company itself that GENR seriously intends to pursue alternative formulations such as nasal or transdermal.

--
Did you listen to today’s webcast. The revelation that GENR is submitting the phase 1/2 Squalamine data to an independent review panel makes me think this was requested by one or more prospective partners. In other words, the Squalamine data was so good that prospective partners wanted to be sure it was real!